돼지 백신 : 시장 점유율 분석, 산업 동향 및 통계 데이터, 성장 예측(2026-2031년)

According to Mordor Intelligence, the swine vaccines market size was valued at USD 1.81 billion in 2025 and estimated to grow from USD 1.9 billion in 2026 to reach USD 2.43 billion by 2031, at a CAGR of 5.03% during the forecast period (2026-2031).

This report is Segmented by Product (Inactivated Vaccines, Attenuated Live Vaccines, Recombinant Vaccines, and Others), Disease Type (Classical Swine Fever (CSF), Porcine Parvovirus, Swine Influenza, and More), Route of Administration (Injectables, Intranasal, and Oral), and Geography (North America, Europe, Asia-Pacific, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Global Swine Vaccines Market Trends and Insights

Government Initiatives Toward Swine-Flu Management & Higher Public Awareness

Mandatory health programs convert voluntary actions into structured prevention plans. The proposed U.S. Swine Health Improvement Plan creates national rules for tracking African swine fever and classical swine fever, rewarding farms that vaccinate . The Philippines issued 10,000 ASF doses under state supervision to test efficacy and build public trust. Taiwan achieved disease-free status for three major swine infections after years of coordinated campaigns, proving that clear government-industry alignment can lower routine vaccination needs. These successes reinforce positive feedback loops: as outbreaks fall, producers keep investing in vaccines to protect market access. In parallel, the incentive to comply grows because vaccinated herds earn smoother domestic movement and export clearance.

Growth in R&D Outlays for Novel Vaccine Platforms

Investment is shifting toward platforms that close gaps in speed and strain coverage. Merck earmarked USD 895 million for Kansas facilities that underpin its RNA particle line, Sequivity. The University of Pittsburgh's trans-amplifying mRNA work shows similar immunity with far less active ingredient, lowering cost per dose. USDA grants fund self-amplifying mRNA projects against ASF and classical swine fever, signaling official support for next-gen approaches. Start-ups push the frontier too; Aptamer Group licensed nanobody adjuvants to boost swine responses. Collectively, rising R&D spend accelerates roll-out of vaccines that are easier to tailor and more economical to scale.

High Cold-Chain Costs & Risk of Adverse Reactions

Temperature-controlled logistics add sizeable expenses, particularly where power grids are unreliable. Freeze-drying research on African swine fever vaccine kept potency for 1 year at 4 °C, but adoption is pending broader field proof . Freeze-preventive cold boxes evaluated in Nepal solved freezing but became heavier and harder to transport over rough terrain. Vietnam's smart-pig trials found vaccination bills between USD 4.7 and 9 per pig, with chilling and handling making up a major share. FAO manuals emphasize that broken cold chains undermine efficacy, leading to revaccination costs and liability concerns. These factors slow uptake among smallholders who operate on thin margins despite clear disease-control benefits.

Other drivers and restraints analyzed in the detailed report include:

1. Escalating Global Pork Consumption & Intensifying Biosecurity Mandates
2. Rapid-Response Autogenous/RNA Platforms Shorten Time-To-Immunity
3. Lengthy, Stringent Regulatory Approval Cycles

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, inactivated vaccines claimed 46.12% of the swine vaccines market share thanks to decades of field success and straightforward production. Recombinant lines post the fastest 5.88% CAGR to 2031 as buyers prize DIVA features that keep trade channels open. Attenuated live options remain in use for robust cellular immunity, though safety rules curtail volumes in high-density farms. Recombinant tools also ease updates when viral genotypes drift beyond current strain panels. The swine vaccines market size for recombinant products is positioned to accelerate as regulators gain experience with platform approvals.

The mRNA wave underscores this tilt toward precision. Sequivity's RNA particles, ready in 12-16 weeks, contrast sharply with classical antigen culture timelines. PEDV spike-mRNA prototypes already trigger stronger responses than inactivated benchmarks. Meanwhile, oral and nanobody-based ideas broaden the "Others" bucket by tackling ease-of-use and stronger mucosal immunity. Together these shifts indicate that future sales will track how quickly each supplier can update antigens while keeping pricing inside producer budgets.

Complete Report Scope:

• By Product
  • Inactivated Vaccines
  • Attenuated Live Vaccines
  • Recombinant Vaccines
  • Others
• By Disease Type
  • Classical Swine Fever (CSF)
  • Porcine Parvovirus
  • Swine Influenza
  • Porcine Circovirus (PCV)
  • Others
• By Route of Administration
  • Injectables
  • Intranasal
  • Oral
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 38.02% of 2025 revenue, supported by strict biosecurity and well-funded producers willing to pay for autogenous and RNA solutions. Federal plans such as the Swine Health Improvement Plan formalize traceability and vaccination compliance. Canada's USD 57.5 million vaccine bank for foot-and-mouth disease signals public investment in rapid response. The swine vaccines market size in North America is also buoyed by a deep cold-chain and dense veterinary service network that ensures uptake.

Asia-Pacific registers the fastest 6.12% CAGR as the region rebuilds inventories after ASF. China's restocking proves that coordinated vaccination, enhanced genetics, and modern barns stabilize supply. The Philippines runs supervised ASF vaccination using a Vietnamese-developed candidate, testing efficacy under field stress. Vietnam's smart-farming push prices vaccination between USD 4.7 and 9 per pig and demonstrates willingness to pay when productivity gains are clear. Thailand's rising pork appetite compounds momentum.

Europe, the Middle East and Africa, and South America offer varied prospects. Europe's FMD cases in 2024 forced emergency vaccine orders that protected export licenses. The bloc's rigorous approval process slows new entrants yet builds end-user confidence, supporting steady demand for premium recombinant products. Middle East and African markets struggle with cold-chain gaps, inviting thermostable formulations. South America's export players adopt DIVA vaccines to secure market access, expanding volume while raising bar for compliance among domestic peers.

1. Merck Animal Health (MSD)
2. Zoetis
3. Boehringer Ingelheim
4. Ceva
5. Elanco
6. Hipra
7. Phibro Animal Health
8. Virbac
9. Vaxxinova
10. Biogenesis Bago
11. KM Biologics
12. Indian Immunologicals
13. Huvepharma
14. IDT Biologika
15. Newport Labs (Boehringer)
16. Epitopix
17. Ouro Fino Saude Animal
18. Jinyu Bio-technology
19. CAHIC (China Animal Husbandry)
20. Ringpu (Ringpu Biotech)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Government Initiatives Toward Swine-Flu Management & Higher Public Awareness
  • 4.2.2 Growth In R&D Outlays for Novel Vaccine Platforms
  • 4.2.3 Escalating Global Pork Consumption & Intensifying Bio-Security Mandates
  • 4.2.4 Rapid-Response Autogenous/RNA Platforms Shorten Time-To-Immunity
  • 4.2.5 AI-Driven Herd Analytics Enable Precision Vaccination & Lower TCO
  • 4.2.6 Trade-Oriented Shift Toward DIVA-Compliant Vaccines
• 4.3 Market Restraints
  • 4.3.1 High Cold-Chain Costs & Risk of Adverse Reactions
  • 4.3.2 Lengthy, Stringent Regulatory Approval Cycles
  • 4.3.3 Viral Genotype Drift Outpacing Vaccine Strain Updates
  • 4.3.4 Budget Diversion To Antibiotic-Free Certification Programs
• 4.4 Regulatory Landscape
• 4.5 Porters Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product
  • 5.1.1 Inactivated Vaccines
  • 5.1.2 Attenuated Live Vaccines
  • 5.1.3 Recombinant Vaccines
  • 5.1.4 Others
• 5.2 By Disease Type
  • 5.2.1 Classical Swine Fever (CSF)
  • 5.2.2 Porcine Parvovirus
  • 5.2.3 Swine Influenza
  • 5.2.4 Porcine Circovirus (PCV)
  • 5.2.5 Others
• 5.3 By Route of Administration
  • 5.3.1 Injectables
  • 5.3.2 Intranasal
  • 5.3.3 Oral
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Merck Animal Health (MSD)
  • 6.3.2 Zoetis Inc.
  • 6.3.3 Boehringer Ingelheim
  • 6.3.4 Ceva Sante Animale
  • 6.3.5 Elanco Animal Health
  • 6.3.6 HIPRA
  • 6.3.7 Phibro Animal Health
  • 6.3.8 Virbac
  • 6.3.9 Vaxxinova
  • 6.3.10 Biogenesis Bago
  • 6.3.11 KM Biologics
  • 6.3.12 Indian Immunologicals
  • 6.3.13 Huvepharma
  • 6.3.14 IDT Biologika
  • 6.3.15 Newport Labs (Boehringer)
  • 6.3.16 Epitopix
  • 6.3.17 Ouro Fino Saude Animal
  • 6.3.18 Jinyu Bio-technology
  • 6.3.19 CAHIC (China Animal Husbandry)
  • 6.3.20 Ringpu (Ringpu Biotech)

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment